Special Issue

Diagnosis, Treatment and Prevention of Gastrointestinal Cancer (2nd Edition)

Message from the Guest Editors

This Special Issue is the second edition of "Diagnosis, Treatment and Prevention of Gastrointestinal Cancer".

The discovery of novel strategies for gastrointestinal cancer diagnosis, treatment and prevention remains a matter of utmost importance. In our efforts to develop effective therapies and anti-cancer drugs, recent research has focused on innovative molecular, biochemical, pathological and immunological developments. Investigation into the mechanisms of carcinogenesis is crucial for the development of cancer screening methods and therapies for application in clinical practice. The discovery of new chemopreventive agents can also help in the fight against cancer.

This issue will present an overview of the most recent studies on advancements in cancer diagnosis, anticancer drugs and chemopreventive agents for gastrointestinal cancers. Topics of interest include (1) cancer diagnosis, (2) carcinogenesis models for the discovery of cancer risk factors, (3) innovative drugs and chemopreventive agents, (4) investigation into the molecular mechanisms of carcinogenesis, (5) the discovery of novel cancer biomarkers and molecular targets, and (6) innovative preclinical studies.

Guest Editors

Dr. Anna Kakehashi

Department of Molecular Pathology, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan

Dr. Min Gi

School of Medicine, Osaka Metropolitan University, Osaka, Japan

Deadline for manuscript submissions

18 February 2026



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/231526

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

